Beaumont Hospital has been approved by the National Cancer Control Programme (NCCP) as a centre for the delivery of cellular therapies for the management of haematological malignancies in adult patients, marking an important step in expanding specialised cancer treatment services.

Cellular therapies, such as CAR T-cells, have the ability to direct immune cells to kill tumour cells within patients. These innovative therapies have produced unprecedented increases in survival and cures in various cancers, particularly for lymphoma and multiple myeloma. New cellular therapies are also in development for solid tumours, brain tumours and non-cancerous conditions, therefore the development of this expertise within the north east region is a hugely positive development for all patients.

The initiative is led by Consultant Haematologists at Beaumont RCSI Cancer Centre, Professor Siobhan Glavey and Professor John Quinn.

Commenting on the announcement, Professor Siobhan Glavey, Beaumont RCSI Cancer Centre, said: “The development of a cellular therapy programme at Beaumont RCSI Cancer Centre is positive news for our cancer patients who will benefit from the most advanced forms of cancer treatment. This new programme builds on our current expertise in cancer and will lead to the development of innovative research in this space.”

Beaumont RCSI Cancer Centre is committed to providing the best cancer service to patients by combining first class clinical care with ground-breaking research and high-quality education and training. The Cancer Centre is made up of Beaumont Hospital, the Royal College of Surgeons in Ireland (RCSI) and St. Luke’s Radiation Oncology Network. Its mission is to provide equitable, individualised quality care to patients with cancer in north Dublin, the north east of Ireland and nationally.